Revance to Participate in Upcoming Investor Conferences - November 6, 2023


NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the following investor conferences.

Stifel 2023 Healthcare Conference
Chief Financial Officer, Tobin Schilke, is scheduled to participate in a fireside chat on Tuesday, November 14, 2023, at 11:30 A.M. EST, in New York City, New York.

Piper Sandler 35th Annual Healthcare Conference
Chief Executive Officer, Mark Foley, is scheduled to participate in a fireside chat on Tuesday, November 28, 2023, at 3:00 P.M. EST, in New York City, New York.

Interested parties can access the live audio webcasts for the conferences from the Investor Relations section of the company's website at The webcast replays will be available after the conclusion of the live presentations for approximately 90 days.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY® in China.

Revance is headquartered in Nashville, Tenn., with additional office locations in Newark and Irvine, Calif.

Learn more at,,,, or connect with us on LinkedIn.

“Revance” and the Revance logo, and DAXXIFY® are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA. BOTOX® is a registered trademark of Allergan, Inc.


Revance Therapeutics, Inc.:
Jessica Serra, 510-279-6886
Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620

Revance Therapeutics, Inc.:
Sara Fahy, 949-887-4476


Source: Revance Therapeutics, Inc.

Back to news